The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.

Table of Contents

1.          Europe Biosimilars Market - Introduction

2.           Europe Biosimilars Market – Key Takeaways

3.          Europe Biosimilars Market - Research Methodology

4.           Europe Biosimilars Market – Market Landscape

5.           Europe Biosimilars Market - Regional Analysis

6.           Europe Biosimilars Market – Revenue and Forecast 

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaborative models are set to be pivotal in helping biosimilar medicine manufacturers maintain a competitive edge in the European market. By teaming up with companies involved in the research, launch, and marketing of biosimilar drugs, manufacturers can rapidly develop and effectively launch their products, thereby mitigating patent risks and fostering trust among clinicians and patients. Such collaborations accelerate product development by providing access to local and foreign expertise, development platforms, and crucial funding for research and clinical trials.

Furthermore, collaborating with a larger biopharmaceutical manufacturer grants access to established manufacturing facilities. This enables the outsourcing of critical activities like cell line development, biologics and biosimilar manufacturing, process scaling, and any necessary technology transfer. These partnerships offer long-term advantages, simplifying the process of tendering for future biosimilar production projects within a country and facilitating early, efficient product development and market penetration. In a diverse and substantial market like Europe, with its significant country-level variations in healthcare policies and market dynamics, gaining local knowledge through these collaborations is incredibly valuable.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00028358

Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologicals represent groundbreaking new therapies for previously incurable diseases and are steadily gaining importance in the pharmaceuticals market. However, patents for many originator biologicals are expected to expire in the coming years.

The impending expiration of patents and other intellectual property rights for originator biologicals will create a pressing need to introduce new biosimilars. As a result, competition among market players will significantly surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create highly lucrative opportunities for the biosimilar market during the forecast period.

Germany currently holds the largest market share in the Europe biosimilars market from 2022-2030. Biosimilars foster competition and enhance the affordability of biologics, ultimately delivering savings and value-added services that support patient care and the healthcare community. This allows healthcare professionals to treat more patients with high-quality biologics while simultaneously reducing expenditures. For example, in Germany, Sandoz reported a 29% increase (from 17.18 to 22.18 million) in the number of daily therapeutic doses of an anti-TNF medicine after biosimilars were introduced in 2022.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications